Medomex® is an inhibitor of free-radical processes, a membrane protector. It also has antihypoxic, stress-protective, nootropic, antiepileptic and anxiolytic effects. It belongs to the class of 3-hydroxypyridines.
The mechanism of action of Medomex® is due to its antioxidant and membrane-protective action. The drug inhibits lipid peroxidation, increases the activity of superoxide oxidase, increases the ratio of lipid-protein, improves the structure and function of the membrane, cells.Medomexi® modulates the activity of membrane-bound enzymes (calcium-independent phosphodiesterase, adenylate cyclase, acetylcholinesterase), receptor complexes (benzodiazepine, GABA, acetylcholine), which enhances their ability to bind to ligands, helps preserve the structural and functional organization of biomembranes, neurotransmitter transport and improve synaptic transmission. Medomex® increases the content of dopamine in the brain. Causes increased activation of compensatory aerobic glycolysis and decreased inhibition of oxidative processes in the Krebs cycle conditions of hypoxia with increasing content of ATP and creatine phosphate, activation energosinteziruyuschih mitochondrial functions.
Increases the resistance of the body to the effect of various damaging factors in pathological conditions (hypoxia and ischemia, cerebral circulation disorders, ethanol intoxication and antipsychotic drugs).
In conditions of a critical decline in coronary blood flow, structurally-functional organization of membranes of cardiomyocytes, stimulates the activity of membrane enzymes, phosphodiesterase, adenylate cyclase, acetylcholinesterase. Supports the activation of acute ischemia activation of aerobic glycolysis and promotes in conditions of hypoxia, the restoration of mitochondrial oxidation-reduction processes, increases the synthesis of ATP and creatine phosphate. Ensures the integrity of the morphological structures and physiological functions of the ischemic myocardium. Improves the clinical course of myocardial infarction, improves the effectiveness of the therapy, reduces the incidence of arrhythmias and violations of intracardiac conduction. Normalizes metabolic processes in the ischemic myocardium, increases the antianginal activity of nitrates, improves the rheological properties of blood, reduces the effects of reperfusion syndrome in acute coronary insufficiency. Reduces enzymatic toxemia and endogenous intoxication in acute pancreatitis. It improves the metabolism and blood supply of the brain, microcirculation and rheological properties of blood, reduces platelet aggregation.Stabilizes the membranes of blood cells (erythrocytes and platelets), reducing the likelihood of hemolysis. Possesses lipid-lowering reduces the content of total cholesterol and low-density lipoproteins.